Bicara Therapeutics (NASDAQ:BCAX) is now covered by analysts at Citizens Jmp. They set a "market perform" rating and a $31.00 price target on the stock.
Bicara Therapeutics (NASDAQ:BCAX) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.
Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at BTIG Research.
Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at UBS Group AG.